Pancreatic Cancer Research

ResearcherLanzhou University Second HospitalActive in the last 2 years

Huaqing Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9982-834X; OpenAlex author ID A5070687412. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers

Papers 9

  1. MMP28 recruits M2-type tumor-associated macrophages through MAPK/JNK signaling pathway-dependent cytokine secretion to promote the malignant progression of pan… Co-author DOI 10.1186/s13046-025-03321-x↗
  2. Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis Co-author DOI 10.21203/rs.3.rs-5324510/v2↗
  3. Long non-coding RNA MIR4435-2HG promotes pancreatic cancer progression by regulating ABHD17C through sponging miR-128-3p. Co-author DOI 10.21037/tcr-24-51↗
  4. Ciprofol suppresses proliferation, invasion and migration of human pancreatic cancer cells. Co-author DOI 10.36721/pjps.2024.37.2.reg.327-336.1↗
  5. Nomograms for Predicting the Risk and Prognosis of Liver Metastases in Pancreatic Cancer: A Population-Based Analysis. Co-author DOI 10.3390/jpm13030409↗
  6. Immunocyte Infiltration Analysis and Immunohistochemistry Identify EVL as a Potential Prognostic Biomarker for Pancreatic Cancer. Co-author DOI 10.3390/jpm13030433↗
  7. Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer. Co-author DOI 10.1002/jcla.24381↗
  8. The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate. Co-author DOI 10.1016/j.bbcan.2022.188826↗
  9. Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression. Co-author DOI 10.3389/fimmu.2022.1038650↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wence Zhou · 6 shared papers, 2022–2024 · strength 1.24
  2. Zhou Chen · 4 shared papers, 2022–2025 · strength 0.93
  3. Yan Du · 4 shared papers, 2022–2025 · strength 0.93
  4. Shi Dong · 4 shared papers, 2022–2024 · strength 0.86
  5. Xin Li · 3 shared papers, 2022–2023 · strength 0.58
  6. Wence Zhou · 2 shared papers, 2024–2025 · strength 0.54
  7. Chunlu Dong · 2 shared papers, 2024–2025 · strength 0.51
  8. Fangfang Han · 2 shared papers, 2024–2025 · strength 0.51
  9. Wenkai Jiang · 2 shared papers, 2023 · strength 0.42
  10. Ru He · 2 shared papers, 2022–2023 · strength 0.36
  11. Shi Dong · 1 shared paper, 2025 · strength 0.30
  12. Chen Zhou · 1 shared paper, 2025 · strength 0.30
  13. Xin Li · 1 shared paper, 2025 · strength 0.30
  14. Wence Zhou · 1 shared paper, 2025 · strength 0.27
  15. Ru He · 1 shared paper, 2024 · strength 0.26
  16. Changpeng Chai · 1 shared paper, 2022 · strength 0.20
  17. Hao Ming Xu · 1 shared paper, 2022 · strength 0.20
  18. Zhengfeng Wang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.